The Global Bovine Respiratory Disease Treatment Market size has been estimated at USD 44.9 million in 2019 and is projected to reach USD 124.6 million by 2024, at a CAGR of 22.4% during the forecast period 2019 - 2024.
The threat of bovine respiratory disease (BRD) has an important effect on the value of cattle in the marketplace. Bovine Respiratory Disease is the most popular and costly disease affecting the beef cattle industry. The disease which affects both lower and upper respiratory tract is referred to as BRD.
BRD is a common term for respiratory disease in cattle caused by a variety of factors. A major cause of economic losses, BRD affects the lower respiratory tract/lungs (pneumonia) or upper respiratory tract (rhinitis, tracheids, bronchitis). The key factor responsible for the disease is stress. Early detection is touted as an important key to treatment success. Bovine respiratory disease (BRD) can be a costly expense for cattle producers. However, it can be avoided by making the use of vaccines.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 - 2024 |
|
Segments Covered |
By Treatment Type & Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co., Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A, Ceva Sante Animale and Vétoquinol S.A. |
This research report on the Global Bovine Respiratory Disease Treatment Market has been segmented and sub-segmented into the following categories and analyzed market size & forecast for each segment until 2024.
Bovine Respiratory Disease Treatment Market Analysis - By Treatment Type
On the basis of treatment type, Antibiotics and anti-inflammatory drugs are now being used for combination treatment and expected to improve the success rate of the treatment.
Regional Analysis:
North America leads the market due to the greater occurrence of bovine respiratory disease. In the Asia Pacific region, China and India have greater cattle adoption and are expected to grow fast.
Companies leading the Global Bovine Respiratory Disease Treatment Market profiled in the report are:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Infectious Agents
5.1.1.1 Antibiotics
5.1.1.2 Sulfas
5.1.2 Anti-Parasiticides
5.1.3 Bronchodilators
5.1.4 Oral Rehydration Fluids
5.1.5 Non-Steroidal Anti-Inflammatories
5.1.6 Mucolytics
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Argentina
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Zoetis Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck & Co. Inc.
8.3 Bayer Corporation
8.4 Eli Lilly & Co.
8.5 Merial S.A.S
8.6 Boehringer Ingelheim Vetmedica
8.7 Novartis Animal Health
8.8 Vibrac S.A
8.9 Ceva Sante Animale
8.10 Vétoquinol S.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
